Carole Estoppey

Title: Carole Estoppey: Innovator in Bispecific Antibodies

Introduction

Carole Estoppey is a prominent inventor based in La Chaux-de-Fonds, Switzerland. She has made significant contributions to the field of immunology, particularly through her innovative work on bispecific antibodies. Her research focuses on developing novel therapeutic solutions for autoimmune and proliferative diseases, including various forms of cancer.

Latest Patents

Carole Estoppey holds a patent for her invention titled "CD47-CD38 bispecific antibodies." This patent describes a class of bispecific heterodimeric immunoglobulins that target both the human CD47 antigen and the human CD38 antigen. The invention includes antibodies that comprise an anti-CD38 heavy chain variable region and a light chain variable region, as well as an anti-CD47 heavy chain variable region and a light chain variable region. The application of these bispecific antibodies is particularly relevant for treating hematologic malignancies and solid tumors.

Career Highlights

Carole Estoppey is associated with Igi Therapeutics SA, where she continues to advance her research in immunotherapy. Her work has the potential to revolutionize treatment options for patients suffering from various cancers and autoimmune disorders. With her innovative approach, she is paving the way for new therapeutic strategies in the medical field.

Collaborations

Carole collaborates with talented professionals in her field, including Laure Bouchez and Blandine Pouleau. These collaborations enhance the research and development of her innovative therapies, contributing to the overall success of her projects.

Conclusion

Carole Estoppey is a trailblazer in the development of bispecific antibodies, with a focus on addressing critical health challenges. Her patent and ongoing work at Igi Therapeutics SA highlight her commitment to advancing medical science and improving patient outcomes.